OBJECTIVE: To determine whether the N363S variant in the glucocorticoid receptor (encoded by nuclear receptor subfamily 3, group C, member 1: NR3C1) is associated with obesity, type 2 diabetes, or hypertension. RESEARCH METHODS AND PROCEDURES: This was a cross-sectional case-control study involving 951 Anglo-Celtic/Northern European subjects from Sydney. This study consisted of the following: 1) an obesity clinic group, most of whom had "morbid obesity" (mean BMI for group = 43 +/- 8 kg/m(2); n = 152); 2) a type 2 diabetes clinic group (n = 356); 3) patients with essential hypertension who had a strong family history (n = 141); and 4) normal healthy controls (n = 302). N363S genotype, BMI, and a range of other parameters relevant to each group were measured. RESULTS: Compared with the frequency of 0.04 in nonobese healthy subjects, the S363 allele was significantly higher in obesity clinic patients (0.17; p = 5.6 x 10(-8)), subjects with diabetes who were also obese (0.09; p = 0.0045), subjects with hypertension who were also overweight (0.08; p = 0.0016), and overweight healthy subjects (0.12; p = 0.0004). DISCUSSION: The NR3C1 N363S variant is associated with obesity and overweight in a range of patient settings but is not associated with hypertension or type 2 diabetes.
OBJECTIVE: To determine whether the N363S variant in the glucocorticoid receptor (encoded by nuclear receptor subfamily 3, group C, member 1: NR3C1) is associated with obesity, type 2 diabetes, or hypertension. RESEARCH METHODS AND PROCEDURES: This was a cross-sectional case-control study involving 951 Anglo-Celtic/Northern European subjects from Sydney. This study consisted of the following: 1) an obesity clinic group, most of whom had "morbid obesity" (mean BMI for group = 43 +/- 8 kg/m(2); n = 152); 2) a type 2 diabetes clinic group (n = 356); 3) patients with essential hypertension who had a strong family history (n = 141); and 4) normal healthy controls (n = 302). N363S genotype, BMI, and a range of other parameters relevant to each group were measured. RESULTS: Compared with the frequency of 0.04 in nonobese healthy subjects, the S363 allele was significantly higher in obesity clinic patients (0.17; p = 5.6 x 10(-8)), subjects with diabetes who were also obese (0.09; p = 0.0045), subjects with hypertension who were also overweight (0.08; p = 0.0016), and overweight healthy subjects (0.12; p = 0.0004). DISCUSSION: The NR3C1N363S variant is associated with obesity and overweight in a range of patient settings but is not associated with hypertension or type 2 diabetes.
Authors: M Tzanela; E Mantzou; K Saltiki; M Tampourlou; N Kalogeris; D Hadjidakis; S Tsagarakis; M Alevizaki Journal: J Endocrinol Invest Date: 2011-07-05 Impact factor: 4.256
Authors: Christine M Jewell; Kevin S Katen; Lisa M Barber; Crystal Cannon; Stavros Garantziotis; John A Cidlowski Journal: Am J Physiol Endocrinol Metab Date: 2016-09-06 Impact factor: 4.310
Authors: Charles C Chung; Lawrence Shimmin; Sivamani Natarajan; Craig L Hanis; Eric Boerwinkle; James E Hixson Journal: J Clin Endocrinol Metab Date: 2008-10-14 Impact factor: 5.958
Authors: O T Eipel; K Németh; D Török; K Csordás; M Hegyi; A Ponyi; A Ferenczy; D J Erdélyi; M Csóka; G T Kovács Journal: Int J Hematol Date: 2013-01-26 Impact factor: 2.490
Authors: Nicolas C Nicolaides; Zoi Galata; Tomoshige Kino; George P Chrousos; Evangelia Charmandari Journal: Steroids Date: 2009-10-07 Impact factor: 2.668